0.18
-3.40%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TScan Therapeutics
From its filings with the US Securities and Exchange Commission
TScan Therapeutics is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TCRX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $10.3m and a net loss of $129.8m. At that date it held total assets of $228.8m and shareholders' equity of $123.1m.
We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The product is designed to eliminate residual disease and promote complete donor chimerism, thereby preventing relapse. TSC-101 targets HA-2, an antigen that is present on all blood cells, malignant or benign, in patients with the HLA type A*02:01. We are currently conducting a Phase 1 clinical study of TSC-101 (the ALLOHA trial, NCT05473910) and during the fourth quarter of 2025, following a productive End-of-Phase meeting with the U.S. Food and Drug Administration (FDA), we reached agreement on a registrational path forward for the TSC-101 program as a potential treatment for patients with AML and MDS. The pivotal study will mirror our ongoing Phase 1 ALLOHA study, using a biologically-assigned (genetically randomized) control arm to support relapse-free survival as the primary endpoint.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jul 2021
- Employees
- 145
- Website
- tscan.com ↗
- Head office
- 830 WINTER STREET, WALTHAM, MA, 02451
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Stephen BiggarIndependent Non-Executive Chairman of the Board$382,374
- Mr. Gavin MacbeathChief Executive Officer, Director$1.8m
- Mr. Jason AmelloChief Financial Officer, Treasurer$3.7m
- Dr. Chrystal LouisChief Medical Officer$3.0m
- Dr. Zoran ZdraveskiChief Legal and Strategy Officer, Secretary$1.6m
- Ms. Katina DortonIndependent Director$376,073
- Dr. Gabriela GruiaIndependent Director$363,573
- Dr. Barbara KlenckeIndependent Director$370,573
- Mr. Garry NicholsonIndependent Director$491,422
- Mr. R. Keith WoodsIndependent Director$361,236
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 53
- Social
- 75
- Governance
- 28
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- TScan Therapeutics has 145 employees focused on TCR-T therapies for liquid cancers and solid tumors.
- TSC-100 and TSC-101 are in clinical development for hematologic malignancies after transplants.
- TScan's ImmunoBank collects solid tumor targets across different HLA types for TCR therapies.
Weaknesses
- TScan Therapeutics' IPO was on 16 July 2021 with limited market history.
- The company has six solid tumor programs in various development stages.
- TScan Therapeutics operates in the competitive US biotechnology sector.
Opportunities
- TSC-204 is entering Phase I development for solid tumors.
- TSC-200 and TSC-203 are in IND-enabling activities for solid tumor treatments.
- TScan's ImmunoBank offers potential for expanding TCR-T therapy applications.
Threats
- TScan Therapeutics faces competition in the US biotechnology sector.
- The company's lead therapies require significant clinical development time.
- TSC-201 is in lead optimization phase for solid tumor programs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.